VG2025
AXP000083.1 · Oncolytic virus
- Platform
- HSV-1 (ICP34.5- ICP47-)
- Originator
- Virogin Biotech
- Sponsor
- Virogin Biotech
Names
| Name | Type | Source |
|---|---|---|
| VG2025 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted
- Transgenes
- IL12A, IL12B, IL15, IL15RA
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C187035
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07682870 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors | Recruiting | Phase 1/2 | 2026-09-04 | 2028-12-02 | 42 | Advanced Malignant Solid Tumor |
| NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | Recruiting | Phase 2 | 2026-08-25 | 2028-01-18 | 30 | Intrahepatic Cholangiocarcinoma |
| NCT07357220 | A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases | Not yet recruiting | Phase 1/2 | 2026-03-02 | 2027-02-28 | 72 | Colorectal Cancer With Hepatic Metastases |
| NCT06365918 | Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis | Withdrawn | Phase 1 | 2024-09-30 | 2024-10-02 | 0 | Advanced Solid Tumor; Carcinomatosis |
| NCT05266612 | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | Unknown | Phase 1 | 2022-11-09 | 2024-12-31 | 12 | Solid Tumor |
| NCT05477849 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors | Recruiting | Phase 1 | 2022-08-23 | 2025-10-31 | 30 | Advanced Malignant Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36938544 | Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1. | Molecular therapy oncolytics | 2023 | name in abstract: VG2025 |
Notes
Second Virogin oHSV: IL-12 and IL-15/IL-15Ralpha, without the PD-L1 blocking peptide of VG161; a distinct construct, so a separate program.
How to cite
VG2025 (AXP000083.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000083.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.